Citizens Memorial Hospital, Heart and Vascular Institute, Bolivar, Missouri; Department of Medicine, University of Missouri, Columbia, Missouri.
University of Arkansas for Medical Sciences, Little Rock, Arkansas.
JACC Cardiovasc Interv. 2015 Nov;8(13):1758-65. doi: 10.1016/j.jcin.2015.07.021.
This study sought to evaluate the safety and efficacy of stent retriever for the management of acute ischemic stroke.
Stroke is the third leading cause of death and the most common cause of disability in the United States. Early reperfusion has been associated with favorable outcomes. Stent retrievers are novel endovascular devices that provide vessel recanalization via thrombus retrieval mechanical thrombectomy.
The authors performed a literature search using PubMed, EMBASE, and Cochrane Central Register of Controlled Trials from May 2005 to May 2015. Randomized controlled trails (RCTs) comparing endovascular therapy (ET) with the use of retrievable stents against standard therapy (ST) for the management of acute stroke were included.
Five RCTs (the MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, and REVASCAT studies) with 634 patients in the ET group and 653 patients in the ST group met inclusion criteria. The frequency of a low 90-day modified Rankin Score (0 to 2) in the intervention group was 42.6% compared with 26.1% in the control group (odds ratio: 2.43; 95% confidence interval [CI]: 1.9 to 3.09; p < 0.0001). The frequency of intracranial bleeding was 4.2% in the ET group compared with 4.3% in the ST group (risk ratio: 1.08; 95% CI: 0.64 to 1.82; p = 0.78). 90-day mortality was 15.1% in the ET group compared with 18.7% in the ST group (risk ratio: 0.81; 95% CI: 0.58 to 1.12; p = 0.19). There was no evidence of significant heterogeneity or publication bias for any of the endpoints.
On the basis of the results of this meta-analysis of RCTs, ET with stent retrievers appears as a safe and effective therapeutic option for acute ischemic stroke due to large vessel occlusion.
本研究旨在评估支架取栓术治疗急性缺血性脑卒中的安全性和疗效。
在美国,脑卒中是第三大致死原因,也是最常见的致残原因。早期再灌注与良好的预后相关。支架取栓术是一种新型的血管内治疗设备,通过血栓抽吸实现机械血栓切除术以恢复血管再通。
作者使用 PubMed、EMBASE 和 Cochrane 对照试验中心数据库检索 2005 年 5 月至 2015 年 5 月的文献。纳入比较血管内治疗(ET)联合可回收支架与标准治疗(ST)治疗急性脑卒中的随机对照试验(RCT)。
5 项 RCT(MR CLEAN、ESCAPE、EXTEND-IA、SWIFT-PRIME 和 REVASCAT 研究)纳入 634 例 ET 组患者和 653 例 ST 组患者。干预组 90 天改良 Rankin 量表(0-2 分)评分较低的频率为 42.6%,对照组为 26.1%(比值比:2.43;95%置信区间:1.9 至 3.09;p<0.0001)。ET 组颅内出血发生率为 4.2%,ST 组为 4.3%(风险比:1.08;95%置信区间:0.64 至 1.82;p=0.78)。ET 组 90 天死亡率为 15.1%,ST 组为 18.7%(风险比:0.81;95%置信区间:0.58 至 1.12;p=0.19)。对于所有终点,均未发现明显的异质性或发表偏倚。
基于这项支架取栓术治疗急性缺血性脑卒中的 RCT 荟萃分析的结果,支架取栓术治疗大血管闭塞性急性缺血性脑卒中安全且有效。